- Home
- WIW vs LXEO Comparison
WIW vs LXEO Comparison
Compare WIW & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | WIW | LXEO |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 518.8M | 486.1M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | WIW | LXEO |
|---|---|---|
| Price | $8.37 | $5.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $18.60 |
| AVG Volume (30 Days) | 212.9K | ★ 767.1K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 11.14% | N/A |
| EPS Growth | N/A | ★ 75.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.33 | $1.45 |
| 52 Week High | $9.03 | $10.99 |
Technical Indicators
Market Signals| Indicator | WIW | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 35.53 | 28.80 |
| Support Level | N/A | $4.93 |
| Resistance Level | $8.84 | $7.77 |
| Average True Range (ATR) | 0.06 | 0.43 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 21.43 | 6.33 |
Price Performance
Historical ComparisonAbout WIW Western Asset Inflation-Linked Opportunities & Income Fund
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income. Capital appreciation, when consistent with current income, is a secondary investment objective. The fund operates as a single operating segment, which is an investment portfolio.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.